💊Telemedicine Regulation for Buprenorphine Treatment Updated
Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
Summary
In the January 17, 2025, issue of the Federal Register, the Drug Enforcement Administration and the Department of Health and Human Services published two final rules related to the practice of telemedicine, titled "Expansion of Buprenorphine Treatment via Telemedicine Encounter" and "Continuity of Care via Telemedicine for Veterans Affairs Patients." These final rules were scheduled to become final on February 18, 2025. In accordance with the Presidential Memorandum of January 20, 2025, titled "Regulatory Freeze Pending Review," the Drug Enforcement Administration and the Department of Health and Human Services are delaying the effective dates of these two final rules to March 21, 2025, and are soliciting public comments specifically regarding this delayed effective date.
Agencies
- Health and Human Services Department
- Justice Department
- Drug Enforcement Administration
Business Impact
$$ - Med
The document outlines regulatory changes affecting the prescribing of controlled substances via telemedicine, which directly impacts compliance and operational procedures for healthcare providers and businesses in the telehealth sector. Businesses must prepare for these new regulations, notably the changes in effective dates and potential implications for continuity of care for patients.